(POE) flanking the POP, leading to the completion of the present invention.

In one aspect, there is provided the use of olanexidine or a pharmacologically acceptable salt thereof for the manufacture of an agent for ameliorating and/or preventing an inflammation (with the proviso that oral mucositis due to treatment of a cancer is excluded).

[0007]

Specifically, the present invention is as follows.

(1) A composition for amelioration and/or prevention of an inflammation, comprising olanexidine or a pharmacologically acceptable salt thereof.

(2) The composition according to (1), wherein the olanexidine or the pharmacologically acceptable salt thereof is olanexidine gluconate.

(3) The composition according to (1) or (2), further comprising a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

(4) The composition according to any one of (1) to (3), wherein the inflammation is selected from stomatitis, oral mucositis, gingivitis, and pneumonia.

(5) The composition according to any one of (1) to (4), wherein

the inflammation is oral mucositis due to treatment of a cancer, and

the composition comprises

0.01 to 1.5% (W/V) of olanexidine gluconate, and

a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

(6) The composition according to any one of (3) to (5), wherein the poloxamer is selected from polyoxyethylene (42) polyoxypropylene (67) glycol (Pluronic P-123), polyoxyethylene (54) polyoxypropylene (39) glycol

CLAIMS

1. Use of olanexidine or a pharmacologically acceptable salt thereof for the manufacture of an agent for ameliorating and/or preventing an inflammation (with the proviso that oral mucositis due to treatment of a cancer is excluded).

2. The use according to claim 1, wherein the olanexidine or the pharmacologically acceptable salt thereof is olanexidine gluconate.

3. The use according to claim 1 or 2, wherein the agent further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

4. The use according to any one of claims 1 to 3, wherein the inflammation is selected from stomatitis, gingivitis, and pneumonia.

5. The use according to claim 3 or 4, wherein the poloxamer is selected from polyoxyethylene (42) polyoxypropylene (67) glycol (Pluronic P-123), polyoxyethylene (54) polyoxypropylene (39) glycol (Pluronic P-85), and polyoxyethylene (196) polyoxypropylene (67) glycol (Pluronic F-127).

6. The use according to claim 5, wherein the poloxamer is polyoxyethylene (42) polyoxypropylene (67) glycol (Pluronic P-123).

7. The use according to any one of claims 1 to 6, wherein a concentration of the olanexidine gluconate is 0.05 to 0.5% (W/V).

8. The composition according to any one of claims 3 to 7, wherein a concentration of the poloxamer is 0.1 to 5.0% (W/V).

9. The composition according to any one of claims 1 to 8, wherein the agent is in a form of a liquid or a gargle.